Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States.

Kota, Vamsi; Ogbonnaya, Augustina; Farrelly, Eileen; Schroader, Bridgette Kanz; Raju, Aditya; Kristo, Fjoralba; Dalal, Mehul

Kota, Vamsi; Ogbonnaya, Augustina; Farrelly, Eileen; Schroader, Bridgette Kanz; Raju, Aditya; Kristo, Fjoralba; Dalal, Mehul.

Affiliation

Kota V; Georgia Cancer Center at Augusta University, Augusta, GA, USA.
Ogbonnaya A; Xcenda LLC, Carrollton, TX, USA. Augustina.ogbonnaya@xcenda.com.
Farrelly E; Xcenda LLC, Carrollton, TX, USA.
Schroader BK; Xcenda LLC, Carrollton, TX, USA.
Raju A; Xcenda LLC, Carrollton, TX, USA.
Kristo F; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Dalal M; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.

Adv Ther ; 40(4): 1655-1669, 2023 04.

Article in En | MEDLINE | ID: mdl-36422807

Subject(s)
Key words

AML; Costs; Higher-risk; MDS; Transformation

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute / Health Care Costs Type of study: Etiology_studies / Health_economic_evaluation / Observational_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Adv Ther Journal subject: TERAPEUTICA Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google